# Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

> **NCT07261683** · PHASE2 · RECRUITING · sponsor: **Obstetrics & Gynecology Hospital of Fudan University** · enrollment: 20 (estimated)

## Conditions studied

- Ovarian Cancer
- Immunotherapy
- Pembrolizumab

## Interventions

- **DRUG:** Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron

## Key facts

- **NCT ID:** NCT07261683
- **Lead sponsor:** Obstetrics & Gynecology Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07261683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07261683, "Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07261683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*